| Revenue growth | ~240% YoY (₹48.92 Cr vs ₹14.38 Cr) |
|---|---|
| Margins | PAT margin ~10.4% vs ~12.2% H1 FY26 |
| Management confidence | Upbeat; 'accelerating business momentum' slide language |
Growth
Revenue ₹48.92 Cr vs ₹14.38 Cr in H1 FY26 (~240%). PAT ₹5.07 Cr vs ₹1.75 Cr (~190%).
Outlook
No numeric guidance; 46% India coverage by Mar-27; 20% own manufacturing by Mar-28; ₹44.9 Cr preferential issue pending.
Risks
Receivables ₹28.6 Cr (+53% vs Mar-26); operating cash flow −₹5.6 Cr; long-term borrowings ₹7.0 Cr vs ₹0.5 Cr; MSME dues ₹7.7 Cr.
Investor Presentation filed with BSE, BSE: 544529. Summary written with AI assistance from the document.
Aptus Pharma Ltd: key numbers
- Share price
- ₹462.70
- Market cap
- ₹793.5 Cr
- Revenue (annual)
- ₹46.57 Cr
- Net profit (annual)
- ₹4.62 Cr
- P/E (TTM)
- 171.8×Sector 46.1×
- Promoter holding
- 72.89%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aptus Pharma Ltd
All →Aptus Pharma H1 FY27 Results: Net Profit ₹5.1 Cr, Up 200.0% YoY
Aptus Pharma Ltd reported revenue from operations of ₹48.9 Cr (+239.6% YoY) and net profit of ₹5.1 Cr (+200.0% YoY) for H1 FY27.
- Key figure
- Net profit ₹5.1 Cr · +200.0% YoY
Aptus Pharma Other Announcement
Aptus Pharma Limited submitted the Regulation 74(5) compliance certificate for the quarter and half-year ended 30th September 2026, as received from its registrar.
Aptus Pharma Annual General Meeting
Aptus Pharma Ltd issued a corrigendum to its 16th AGM notice regarding inadvertent errors in the explanatory statement for item no. 3.
Aptus Pharma Fund Raise of ₹44.88 Cr
Aptus Pharma Limited's Board has approved raising ₹44.88 Crore through a preferential equity issue. Funds will support manufacturing capacity expansion, working capital, and Pan-India growth initiatives.
- Value
- ₹44.88 Cr
- Execution
- 36 months
Aptus Pharma Annual Report
Aptus Pharma has filed its Annual Report for FY 2025-26 with the exchange. The report includes the notice for the upcoming 16th Annual General Meeting.
Aptus Pharma Annual General Meeting
Aptus Pharma Limited issued a notice for its 16th AGM on September 14, 2026, which includes a proposal for a preferential allotment of equity shares.
- Value
- ₹44.88 Cr